Myelodysplastic Syndromes

78 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Hematologic Diseases

Narrower: Anemia, Refractory, with Excess of Blasts 12, GATA2 Deficiency 2, Hemoglobinuria, Paroxysmal 3

Treatments and conditions

Myelodysplastic Syndromes
Treatment and conditionWhere it standsTrials
AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abatacept for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ascorbic Acid for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASTX727 for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
ATO + Ascorbic acid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Ascorbic Acid for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 + Posaconazole for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danicopan for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Darbepoetin alfa + canakinumab for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic stem-cell transplantation for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immediate HSCT Group for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Momelotinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nk-dli for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pozelimab + cemdisiran for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton Total Marrow Irradiation for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Romiplostim for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rosuvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxoprubart for hemoglobinuria, paroxysmalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.